MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Closed 10-31 16:00:00 EDT

2.78

-0.02

-0.71%

盘后2.78

+0.000.00%

18:39 EDT

High2.85	Low2.70	Vol26.11K
Open2.85	D1 Closing2.80	Amplitude5.36%
Mkt Cap66.63M	Tradable Cap54.30M	Total Shares23.97M
T/O72.10K	T/O Rate0.13%	Tradable Shares19.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":2.78,"timestamp":1730404800000,"preClose":2.8,"halted":0,"volume":26113,"hourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.78,"latestTime":"18:39 EDT","volume":2,"amount":5.76,"timestamp":1730414372523},"delay":0,"floatShares":19530626,"shares":23966814,"eps":-1.627876,"marketStatus":"Closed","change":-0.02,"latestTime":"10-31 16:00:00 EDT","open":2.85,"high":2.85,"low":2.7,"amount":72095.9248504,"amplitude":0.053571,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.627876,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730448000000},"marketStatusCode":5,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":2.8,"postHourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.78,"latestTime":"18:39 EDT","volume":2,"amount":5.76,"timestamp":1730414372523},"volumeRatio":0.331598},"requestUrl":"/m/hq/s/MAIA/tweets","defaultTab":"tweets","newsList":[{"id":"2479170464","title":"Maia Biotechnology Announces $2.44 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479170464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479170464?lang=en_us&edition=fundamental","pubTime":"2024-10-29 07:00","pubTimestamp":1730156402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nTUA862FDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2479546216","title":"MAIA Biotechnology Announces $2.44 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479546216","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479546216?lang=en_us&edition=fundamental","pubTime":"2024-10-29 07:00","pubTimestamp":1730156400,"startTime":"0","endTime":"0","summary":"CHICAGO, October 28, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,079,784 shares of common stock at a purchase price of $2.259 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.51 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed . The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The securities being sold to the Company director participating in the offering are being issued pursuant to the Company’s 2021 Equity Incentive Plan. The private placement is expect","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/St6JsPneDkypf7QFywxcyg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/08e3b01955bf3949f443fbe29da395be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/St6JsPneDkypf7QFywxcyg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/08e3b01955bf3949f443fbe29da395be"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-2-44-230000879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2478962585","title":"Vlad Vitoc Reports 13.29% Stake in Maia Biotechnology Inc as of Oct 25 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2478962585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478962585?lang=en_us&edition=fundamental","pubTime":"2024-10-26 05:13","pubTimestamp":1729890816,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nFWN3M129D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2475506116","title":"MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2475506116","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475506116?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:15","pubTimestamp":1728994500,"startTime":"0","endTime":"0","summary":"MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trials. CHICAGO, October 15, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract related to the company’s second generation of proprietary telomere-targeting THIO prodrugs has been accepted for poster presentation during the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 23-25, 2024, in Barcelona, Spain. The Symposium is hosted by the European Organisation for Research and Treatment of Cancer , the National Cancer Institute  and the American Association for Cancer Research .MAIA’s Chief Scientific Officer Sergei Gryaznov, Ph.D. commented, \"Our presentation will demonstrate that treatment with each of the prodrugs studied was highly efficacious and was shown to overcome immunotherapy resistance. Our results have shown marked activity in ad","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vnINyXvtSySTz9DP6rYHvg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6cd47cad594db671a11ba737714224c3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vnINyXvtSySTz9DP6rYHvg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6cd47cad594db671a11ba737714224c3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-poster-presentation-121500141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","MAIA","LENZ","BK4588","L","BK4139","LU0053666078.USD","NCI","BK4585","BK4202"],"gpt_icon":0},{"id":"2466272928","title":"Noble Financial Reaffirms Their Buy Rating on MAIA Biotechnology, Inc. (MAIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466272928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466272928?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:25","pubTimestamp":1726143925,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-reaffirms-their-buy-rating-on-maia-biotechnology-inc-maia-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-reaffirms-their-buy-rating-on-maia-biotechnology-inc-maia-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBL","MAIA"],"gpt_icon":0},{"id":"2466436363","title":"BRIEF-MAIA Biotechnology Announces Positive Survival Updates In Phase 2 Study Of Thio In Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2466436363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466436363?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:17","pubTimestamp":1725967024,"startTime":"0","endTime":"0","summary":"Sept 10  - Maia Biotechnology Inc   :   * MAIA BIOTECHNOLOGY ANNOUNCES POSITIVE SURVIVAL UPDATES IN PHASE 2 STUDY OF THIO IN NON-SMALL CELL LUNG CANCER   * MAIA BIOTECHNOLOGY INC - 16 PATIENTS SURPASSED 12-MONTH SURVIVAL FOLLOW-UP   * MAIA BIOTECHNOLOGY INC - THIO FOLLOWED BY LIBTAYO GENERALLY WELL-TOLERATED   * MAIA BIOTECHNOLOGY INC - EXPECTS TO RELEASE FULL EFFICACY RESULTS OF THIO-101 THIS YEARSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2466865433","title":"MAIA Biotechnology Advances with Clinical Trials and Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2466865433","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466865433?lang=en_us&edition=fundamental","pubTime":"2024-09-10 18:48","pubTimestamp":1725965286,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an announcement. MAIA Biotechnology, Inc. is actively engaging with the financial community, presen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-advances-with-clinical-trials-and-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-advances-with-clinical-trials-and-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2466822684","title":"Maia Biotechnology Inc - 16 Patients Surpassed 12-Month Survival Follow-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2466822684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466822684?lang=en_us&edition=fundamental","pubTime":"2024-09-10 18:00","pubTimestamp":1725962401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA9CSSGM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2466822524","title":"Maia Biotechnology Inc - Expects to Release Full Efficacy Results of Thio-101 This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2466822524","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466822524?lang=en_us&edition=fundamental","pubTime":"2024-09-10 18:00","pubTimestamp":1725962401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA9CSSGM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2466482285","title":"Maia Biotechnology Announces Positive Survival Updates in Phase 2 Study of Thio in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2466482285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466482285?lang=en_us&edition=fundamental","pubTime":"2024-09-10 18:00","pubTimestamp":1725962401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA9CSSGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2466482254","title":"Maia Biotechnology Inc - Thio Followed by Libtayo Generally Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2466482254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466482254?lang=en_us&edition=fundamental","pubTime":"2024-09-10 18:00","pubTimestamp":1725962401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA9CSSGM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2466872994","title":"MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2466872994","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466872994?lang=en_us&edition=fundamental","pubTime":"2024-09-10 18:00","pubTimestamp":1725962400,"startTime":"0","endTime":"0","summary":"THIO's substantial survival benefit in third line surpasses comparable standard-of-care overall survival of 5.8 months. Median survival follow-up in third line was 10.6 months. Treatment with THIO followed by Libtayo has been generally well-tolerated to date. THIO  is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer . Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine  induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate  and adaptive  immune responses. The sequential treatment with THIO followed by PD-1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer mode","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ILaJ47cB9p_O6MBcQe9Mjg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b89024d2a2896a12a3194c52e9b886c3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ILaJ47cB9p_O6MBcQe9Mjg--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b89024d2a2896a12a3194c52e9b886c3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-positive-survival-100000548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PFS","LU0053666078.USD","BK4588","OS","BK4097","CPI","BK4585","BK4195","L","MAIA","BK4107","BK4211"],"gpt_icon":0},{"id":"2464374515","title":"MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2464374515","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464374515?lang=en_us&edition=fundamental","pubTime":"2024-09-04 20:30","pubTimestamp":1725453000,"startTime":"0","endTime":"0","summary":"Updates from THIO-101 to include response rates and survival follow-up. CHICAGO, September 04, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City.Dr. Vitoc’s presentation will reveal the latest clinical data from MAIA’s Phase 2 THIO-101 clinical trial of lead candidate THIO sequenced with the immune checkpoint inhibitor cemiplimab  in patients with advanced non-small cell lung cancer  who failed 2 or more standard-of-care therapy regimens.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vMi3G.LLIAkCfiW9iBqs3Q--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8d78b7b850d6560d6b1441217b6781e8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vMi3G.LLIAkCfiW9iBqs3Q--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8d78b7b850d6560d6b1441217b6781e8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-present-phase-2-123000065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","BK4585","L","MAIA","BK4588","BK4107","BK4139"],"gpt_icon":0},{"id":"2453033469","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2453033469","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453033469?lang=en_us&edition=fundamental","pubTime":"2024-07-23 19:49","pubTimestamp":1721735397,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4157","BK4571","TUSK","BK4585","BK4548","LU2360107168.USD","BK4139","BK4179","FEIM","LU2290526834.HKD","MESO","SPOT","LU1861215975.USD","BK4084","BK4588","PW","BK4234","LU1861220033.SGD","MAIA","BK4108"],"gpt_icon":0},{"id":"2453113081","title":"MAIA Biotechnology Says Cancer Treatment Agent Was Well Tolerated in Mid-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2453113081","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453113081?lang=en_us&edition=fundamental","pubTime":"2024-07-23 18:14","pubTimestamp":1721729654,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["MAIA","SSI","BK4139"],"gpt_icon":0},{"id":"2453081433","title":"MAIA Biotechnology Says Cancer Treatment Agent Was Well Tolerated in Mid-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2453081433","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453081433?lang=en_us&edition=fundamental","pubTime":"2024-07-23 18:14","pubTimestamp":1721729654,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology  said Tuesday that a combination of THIO and cemiplimab was well tolerated in patients with advanced non-small cell lung cancer in a phase 2 trial.Results of the trial showed the safety, efficacy and ongoing benefit of the oncology therapy, the company said.Six patients remain on treatment after more than 12 months of therapy, according to the company.Price: 4.4000, Change: +0.65, Percent Change: +17.33","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","MAIA"],"gpt_icon":0},{"id":"2453908817","title":"Maia Biotechnology Announces New Updates From Phase 2 Trial of Novel Cancer Treatment Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2453908817","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453908817?lang=en_us&edition=fundamental","pubTime":"2024-07-23 16:11","pubTimestamp":1721722260,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Announces New Updates From Phase 2 Trial of Novel Cancer Treatment Agent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240723:nTUA3YTXSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2453088128","title":"MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2453088128","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453088128?lang=en_us&edition=fundamental","pubTime":"2024-07-23 16:11","pubTimestamp":1721722260,"startTime":"0","endTime":"0","summary":"THIO followed by cemiplimab shown to be well tolerated throughout trial, with far lower toxicity compared to standard of care treatments. 6 patients on trial regimen for more than 12 months have completed up to 21 cycles, with treatment ongoing. CHICAGO, July 23, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor  cemiplimab  in patients with advanced non-small cell lung cancer  who failed two or more standard-of-care therapy regimens.THIO  is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer . Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GpZw8CuxtYtn.Gx1dzTdlw--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c6ea687d5955aba68bb6474780207c4f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GpZw8CuxtYtn.Gx1dzTdlw--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c6ea687d5955aba68bb6474780207c4f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-updates-phase-081100156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4107","MAIA","BK4585","LU0053666078.USD","L","CPI","BK4139"],"gpt_icon":0},{"id":"2441009959","title":"MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2441009959","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441009959?lang=en_us&edition=fundamental","pubTime":"2024-06-08 01:12","pubTimestamp":1717780320,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology shares rose after the company said telomere targeting functionality, used by its THIO candidate, was shown to be viable by the Food and Drug Administration's approval of a telomerase inhibitor agent therapy.Shares were up 14% to $3.79 in recent trading.The company said the clinical and regulatory pathways for viable therapies leveraging the cell's telomeric functions have been validated by the FDA's approval of imetelstat, a treatment for low- to intermediate-risk hematologic malignancies, or myelodysplastic syndromes, from Geron Corp.The FDA approved imetelstat for rare blood cancers originating in bone marrow.\"We have found that telomere targeting as a mechanism of action plays a key role in treating certain cancers,\" said MAIA Chief Executive Vlad Vitoc. \"We are studying this science in our Phase 2 trial of THIO in high-risk non-small cell lung cancer, or NSCLC.MAIA's lead candidate is THIO, a telomere targeting agent in Phase 2 clinical development to evaluate it","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2441913095","title":"Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2441913095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441913095?lang=en_us&edition=fundamental","pubTime":"2024-06-08 00:31","pubTimestamp":1717777873,"startTime":"0","endTime":"0","summary":"Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240607:nFWN3I50IW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maiabiotech.com","stockEarnings":[{"period":"1week","weight":0.0526},{"period":"1month","weight":-0.0036},{"period":"3month","weight":-0.0968},{"period":"6month","weight":-0.1463},{"period":"1year","weight":0.3527},{"period":"ytd","weight":1.3932}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.0108},{"period":"3month","weight":0.068},{"period":"6month","weight":0.1342},{"period":"1year","weight":0.3867},{"period":"ytd","weight":0.2201}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}